de Martimprey H, Vauthier C, Malvy C, Couvreur P
Univ. Paris-Sud, Chatenay-Malabry, France.
Eur J Pharm Biopharm. 2009 Mar;71(3):490-504. doi: 10.1016/j.ejpb.2008.09.024. Epub 2008 Nov 1.
The success of the application of new therapeutic methods based on RNA interfering strategies requires the in vivo delivery of active ODN or siRNA down to the intracellular compartment of the target cells. This article aims to review the studies related to the formulation of RNA interfering agents in polymer nanocarriers. It will present the different types of polymer nanocarriers used as well as the biological activity of the resulting ODN and siRNA loaded nanocarriers. As will be explained, the part of the in vitro studies provided useful data about the intracellular delivery of the formulated RNA interfering agents. Investigations performed in vivo have considered animal models of different relevant diseases. Results from these investigations have clearly demonstrated the interest of several polymer nanocarriers tested so far to deliver active RNA interfering effectors in vivo making possible their administration by the intravenous route.
基于RNA干扰策略的新治疗方法的成功应用需要将活性寡核苷酸(ODN)或小干扰RNA(siRNA)在体内递送至靶细胞的细胞内区室。本文旨在综述与聚合物纳米载体中RNA干扰剂配方相关的研究。它将介绍所使用的不同类型的聚合物纳米载体以及所得负载ODN和siRNA的纳米载体的生物活性。如将解释的那样,体外研究部分提供了有关所配制的RNA干扰剂细胞内递送的有用数据。体内进行的研究考虑了不同相关疾病的动物模型。这些研究的结果清楚地表明了迄今为止测试的几种聚合物纳米载体在体内递送活性RNA干扰效应物的价值,使其能够通过静脉途径给药。